(CLA-B) Cloetta (publ) - Ratings and Ratios
Chocolate, Confectionery, Pastilles, ChewingGum, Nuts
CLA-B EPS (Earnings per Share)
CLA-B Revenue
Description: CLA-B Cloetta (publ)
Cloetta AB (publ) is a confectionery company operating in multiple segments, including Branded Packaged Products and Pick & Mix. The company manufactures and markets a diverse range of chocolate confectionery products, confectionery products, pastilles, and chewing gums under various brands such as Kexchoklad, Malaco, Läkerol, and Jenkki.
The companys product portfolio is diversified across categories, with a presence in multiple geographies, including Sweden, Finland, the Netherlands, Denmark, Norway, Germany, and the United Kingdom. Cloetta AB (publ) sells its products through various sales channels, including grocery retail trade, service trade, e-commerce, and other channels.
From a financial perspective, Cloetta AB (publ) has a Market Cap of 9897.44M SEK, indicating a significant presence in the market. The companys P/E ratio is 14.40, suggesting a relatively reasonable valuation. Additionally, the RoE of 12.22% indicates a decent return on equity, suggesting that the company is generating profits from its shareholders investments.
To further analyze the companys performance, other key performance indicators (KPIs) such as revenue growth, gross margin, operating margin, and dividend yield can be considered. For instance, a high gross margin would indicate the companys ability to maintain pricing power and control costs, while a stable operating margin would suggest effective cost management. A consistent dividend yield would also be attractive to income-seeking investors.
Overall, Cloetta AB (publ) appears to be a well-established player in the confectionery industry with a diversified product portfolio and presence in multiple geographies. Further analysis of the companys financials and KPIs would be necessary to determine its investment potential.
CLA-B Stock Overview
| Market Cap in USD | 995m |
| Sub-Industry | Packaged Foods & Meats |
| IPO / Inception |
CLA-B Stock Ratings
| Growth Rating | 58.2% |
| Fundamental | 76.3% |
| Dividend Rating | 70.2% |
| Return 12m vs S&P 500 | 24.5% |
| Analyst Rating | - |
CLA-B Dividends
| Dividend Yield 12m | 3.71% |
| Yield on Cost 5y | 5.80% |
| Annual Growth 5y | 14.87% |
| Payout Consistency | 90.1% |
| Payout Ratio | 60.1% |
CLA-B Growth Ratios
| Growth Correlation 3m | -66.5% |
| Growth Correlation 12m | 88.8% |
| Growth Correlation 5y | 21.2% |
| CAGR 5y | 11.41% |
| CAGR/Max DD 5y | 0.29 |
| Sharpe Ratio 12m | -0.15 |
| Alpha | 0.14 |
| Beta | 0.571 |
| Volatility | 19.34% |
| Current Volume | 185.4k |
| Average Volume 20d | 253.3k |
| Stop Loss | 31.5 (-3.1%) |
| Signal | 1.75 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (657.0m TTM) > 0 and > 6% of Revenue (6% = 515.9m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 0.12pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -7.91% (prev 15.43%; Δ -23.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 809.0m > Net Income 657.0m (YES >=105%, WARN >=100%) |
| Net Debt (1.64b) to EBITDA (991.0m) ratio: 1.65 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (285.0m) change vs 12m ago -0.34% (target <= -2.0% for YES) |
| Gross Margin 35.59% (prev 31.64%; Δ 3.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 79.36% (prev 78.50%; Δ 0.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.65 (EBITDA TTM 991.0m / Interest Expense TTM 171.0m) >= 6 (WARN >= 3) |
Altman Z'' -0.06
| (A) -0.06 = (Total Current Assets 3.51b - Total Current Liabilities 4.19b) / Total Assets 10.89b |
| (B) -0.13 = Retained Earnings (Balance) -1.40b / Total Assets 10.89b |
| (C) 0.07 = EBIT TTM 796.0m / Avg Total Assets 10.83b |
| (D) 0.26 = Book Value of Equity 1.44b / Total Liabilities 5.49b |
| Total Rating: -0.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.29
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 6.08% = 3.04 |
| 3. FCF Margin 7.75% = 1.94 |
| 4. Debt/Equity 0.44 = 2.40 |
| 5. Debt/Ebitda 2.40 = -0.78 |
| 6. ROIC - WACC 12.28% = 12.50 |
| 7. RoE 12.22% = 1.02 |
| 8. Rev. Trend 67.00% = 3.35 |
| 9. Rev. CAGR 5.40% = 0.68 |
| 10. EPS Trend 44.86% = 1.12 |
| 11. EPS CAGR -3.81% = -0.48 |
What is the price of CLA-B shares?
Over the past week, the price has changed by -0.61%, over one month by +3.17%, over three months by -6.87% and over the past year by +47.01%.
Is Cloetta (publ) a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLA-B is around 32.47 SEK . This means that CLA-B is currently overvalued and has a potential downside of -0.15%.
Is CLA-B a buy, sell or hold?
What are the forecasts/targets for the CLA-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23 | -29.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 35.1 | 8% |
CLA-B Fundamental Data Overview
Market Cap SEK = 9.38b (9.38b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 815.0m SEK (Cash And Short Term Investments, last quarter)
P/E Trailing = 14.0
P/S = 1.091
P/B = 1.7166
Beta = 0.825
Revenue TTM = 8.60b SEK
EBIT TTM = 796.0m SEK
EBITDA TTM = 991.0m SEK
Long Term Debt = -4.00m SEK (from longTermDebt, last quarter)
Short Term Debt = 2.39b SEK (from shortTermDebt, last quarter)
Debt = 2.38b SEK (Calculated: Short Term 2.39b + Long Term -4.00m)
Net Debt = 1.64b SEK (from netDebt column, last quarter)
Enterprise Value = 10.95b SEK (9.38b + Debt 2.38b - CCE 815.0m)
Interest Coverage Ratio = 4.65 (Ebit TTM 796.0m / Interest Expense TTM 171.0m)
FCF Yield = 6.08% (FCF TTM 666.0m / Enterprise Value 10.95b)
FCF Margin = 7.75% (FCF TTM 666.0m / Revenue TTM 8.60b)
Net Margin = 7.64% (Net Income TTM 657.0m / Revenue TTM 8.60b)
Gross Margin = 35.59% ((Revenue TTM 8.60b - Cost of Revenue TTM 5.54b) / Revenue TTM)
Tobins Q-Ratio = 7.59 (Enterprise Value 10.95b / Book Value Of Equity 1.44b)
Interest Expense / Debt = 1.30% (Interest Expense 31.0m / Debt 2.38b)
Taxrate = 27.62% (182.0m / 659.0m)
NOPAT = 576.2m (EBIT 796.0m * (1 - 27.62%))
Current Ratio = 0.84 (Total Current Assets 3.51b / Total Current Liabilities 4.19b)
Debt / Equity = 0.44 (Debt 2.38b / last Quarter total Stockholder Equity 5.40b)
Debt / EBITDA = 2.40 (Net Debt 1.64b / EBITDA 991.0m)
Debt / FCF = 3.58 (Debt 2.38b / FCF TTM 666.0m)
Total Stockholder Equity = 5.38b (last 4 quarters mean)
RoA = 6.03% (Net Income 657.0m, Total Assets 10.89b )
RoE = 12.22% (Net Income TTM 657.0m / Total Stockholder Equity 5.38b)
RoCE = 14.81% (Ebit 796.0m / (Equity 5.38b + L.T.Debt -4.00m))
RoIC = 18.90% (NOPAT 576.2m / Invested Capital 3.05b)
WACC = 6.62% (E(9.38b)/V(11.76b) * Re(8.06%)) + (D(2.38b)/V(11.76b) * Rd(1.30%) * (1-Tc(0.28)))
Shares Correlation 5-Years: -90.0 | Cagr: -0.31%
Discount Rate = 8.06% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 79.25% ; FCFE base≈658.0m ; Y1≈705.9m ; Y5≈862.0m
Fair Price DCF = 53.49 (DCF Value 15.03b / Shares Outstanding 280.9m; 5y FCF grow 8.16% → 3.0% )
Revenue Correlation: 67.00 | Revenue CAGR: 5.40%
Rev Growth-of-Growth: -9.31
EPS Correlation: 44.86 | EPS CAGR: -3.81%
EPS Growth-of-Growth: 11.16